Clinical Trials Logo
  1. Home
  2. Migraine
  3. NCT04804995
  4. Details
NCT04804995 Clinical Trial

Investigating the Frequency and Phenotype of Headaches Associated With Fasting During the Month of Ramadan.

Migraine Clinical Trial

Official title:
Headache in Ramadan.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04804995
Other study ID # Ramadan2021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 16, 2021
Est. completion date June 30, 2021

Study information
Verified date November 2022
Source Danish Headache Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Headaches are more common in the month of Ramadan in patients who already suffer from migraine. The object of the present study is investigate the frequency in the Ramadan month .

Recruitment information / eligibility
Status Completed
Enrollment 134
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - age 18-60 years. - expectation of fasting for at least 21 of 30 days during the month of Ramadan. - understand and answer the questionnaire sent out in Danish. Exclusion Criteria: - non-compliance with the headache calendar (defined as non-registration of at least 21 days per 30 days).

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• There is no intervention.
No intervention.

Locations
Country Name City State
Denmark Danish Headache Center Glostrup

Sponsors (1)
Lead Sponsor Collaborator
Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary Headache frequency The frequency of headaches is higher in the first half of Ramadan month compared to the last half. Daily headache diary in three months.
Primary Headache frequency The frequency of headaches is higher in the month before Ramadan compared to the month after ramadan. Daily headache diary in three months.
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A